Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 4/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 7/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.40 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.40 |
| ▸ | DNPH1 | O43598 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26291926 | 1.00 | RNASEL (0.46) | RNASELP2RY2P2RY4P2RY14P2RY12 | |
| SCHEMBL26294878 | 1.00 | RNASEL (0.46) | RNASELP2RY2P2RY4P2RY14P2RY12 | |
| SCHEMBL30292621 | 0.97 | RNASEL (0.45) | RNASELP2RY2P2RY4P2RY14P2RY12 | |
| SCHEMBL20778026 | 0.97 | RNASEL (0.45) | RNASELP2RY2P2RY4P2RY14P2RY12 | |
| SCHEMBL26442453 | 0.97 | RNASEL (0.45) | RNASELP2RY2P2RY4P2RY14P2RY12 | |
| SCHEMBL21274766 | 0.94 | RNASEL (0.46) | RNASELP2RY2P2RY4P2RY14P2RY12 | |
| SCHEMBL21307917 | 0.94 | RNASEL (0.46) | RNASELP2RY2P2RY4P2RY14P2RY12 | |
| SCHEMBL21274283 | 0.91 | RNASEL (0.40) | RNASELP2RY2P2RY4P2RY14P2RY12 | |
| SCHEMBL22375444 | 0.91 | RNASEL (0.40) | RNASELP2RY2P2RY4P2RY14P2RY12 | |
| SCHEMBL21307774 | 0.91 | RNASEL (0.40) | RNASELP2RY2P2RY4P2RY14P2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584774-B2 | Compounds, compositions, and methods for the treatment of disease | F-star Therapeutics, Inc. (GB) | 2023-02-21 | — | — | US | disclosed |
| US-20200270299-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | INVOX PHARMA LIMITED (GB) | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270299-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF DISEASE | STING1, MAVS, IRF3 | RNASEL 1374/4885P2RY2 1016/4885P2RY4 1082/4885 |
| US-11584774-B2 | Compounds, compositions, and methods for the treatment of disease | STING1, MAVS, IRF3 | RNASEL 1374/4885P2RY2 1016/4885P2RY4 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.